Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications.
The company markets an innovative portfolio of solutions including the TetraGraph® and ExSpiron® 2Xi, for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year.
Senzime operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI).
Explore our patient monitoring solutions
Get product details
How can Senzime’s products help to eliminate in-hospital complications?
Contact us to discuss your needs or schedule a product demo.